To further explore the effects of the complement receptors in mammary cancer, we used two syngeneic murine mammary carcinoma models: EMT6, which is weakly estrogen receptor (ER)-positive [33], and 4T1, a model of triple-negative breast cancer [34]. Here, ESR1 is linked to breast carcinoma.